The Supreme Court has intervened suo motu to address judicial delays in cases concerning access to life-saving drugs, specifically highlighting a Kerala HC matter on Ribociclib (breast cancer drug) listed 57 times without conclusion. This directly links to Article 21 (Right to Life) and raises critical issues of access to affordable medicines, patent law, and judicial efficiency.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›SC Case Title: In Re: Access to Life Saving Medicines and Judicial Expediency in Article 21 Matters
- ›Drug Name: Ribociclib (for HR-positive, HER2-negative breast cancer)
- ›Target this Data: ₹78,468 per month cost of Ribociclib; listed 57 times without conclusion
- ›Target this Nodal Body: Supreme Court (CJI Surya Kant bench) and Kerala High Court
- ›Target this Legal Point: Article 21 (Right to Life) and Patents Act government-use licence
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.